Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
OPHT's Cash to Debt is ranked higher than
74% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. OPHT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OPHT' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset -0.10
OPHT's Equity to Asset is ranked lower than
94% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OPHT: -0.10 )
Ranked among companies with meaningful Equity to Asset only.
OPHT' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.18 Max: 0.36
Current: -0.1
-0.1
0.36
Interest Coverage No Debt
OPHT's Interest Coverage is ranked higher than
66% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPHT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -2.31
M-Score: -3.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -336.93
OPHT's Operating margin (%) is ranked lower than
64% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. OPHT: -336.93 )
Ranked among companies with meaningful Operating margin (%) only.
OPHT' s Operating margin (%) Range Over the Past 10 Years
Min: -336.93  Med: -217.49 Max: -195.14
Current: -336.93
-336.93
-195.14
Net-margin (%) -323.19
OPHT's Net-margin (%) is ranked lower than
65% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. OPHT: -323.19 )
Ranked among companies with meaningful Net-margin (%) only.
OPHT' s Net-margin (%) Range Over the Past 10 Years
Min: -323.19  Med: -244.14 Max: -205.26
Current: -323.19
-323.19
-205.26
ROE (%) -527.85
OPHT's ROE (%) is ranked lower than
98% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. OPHT: -527.85 )
Ranked among companies with meaningful ROE (%) only.
OPHT' s ROE (%) Range Over the Past 10 Years
Min: -527.85  Med: -112.18 Max: -78.3
Current: -527.85
-527.85
-78.3
ROA (%) -40.40
OPHT's ROA (%) is ranked lower than
59% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. OPHT: -40.40 )
Ranked among companies with meaningful ROA (%) only.
OPHT' s ROA (%) Range Over the Past 10 Years
Min: -241.11  Med: -45.96 Max: -23.27
Current: -40.4
-241.11
-23.27
ROC (Joel Greenblatt) (%) -2283.80
OPHT's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. OPHT: -2283.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPHT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -26895.89  Med: -16410.03 Max: -2283.8
Current: -2283.8
-26895.89
-2283.8
GuruFocus has detected 3 Warning Signs with Ophthotech Corp $OPHT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPHT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

OPHT Guru Trades in Q4 2015

Samuel Isaly 331,000 sh (unchged)
Jim Simons 301,415 sh (-20.15%)
Pioneer Investments 83,168 sh (-34.96%)
» More
Q1 2016

OPHT Guru Trades in Q1 2016

Steven Cohen 414,400 sh (New)
Paul Tudor Jones 11,296 sh (New)
Jim Simons 362,500 sh (+20.27%)
Samuel Isaly 331,000 sh (unchged)
Pioneer Investments 64,092 sh (-22.94%)
» More
Q2 2016

OPHT Guru Trades in Q2 2016

Samuel Isaly 331,000 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Pioneer Investments 63,987 sh (-0.16%)
Paul Tudor Jones 10,501 sh (-7.04%)
» More
Q3 2016

OPHT Guru Trades in Q3 2016

Steven Cohen 786,300 sh (New)
Pioneer Investments 86,992 sh (+35.95%)
Paul Tudor Jones 7,094 sh (-32.44%)
Samuel Isaly 284,600 sh (-14.02%)
» More
» Details

Insider Trades

Latest Guru Trades with OPHT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AGTC, NAS:DVAX, OTCPK:SIGA, OTCPK:OGRMF, NAS:RDHL, NAS:NVLN, NAS:CDTX, NAS:ABUS, OTCPK:TYMI, NAS:APEN, NAS:AVXL, NAS:VTVT, NAS:CEMP, OTCPK:PRMCF, OTCPK:PAIOF, OTCPK:HSDT, NAS:CTIC, NAS:IMDZ, NAS:VTL, OTCPK:SPHRF » details
Traded in other countries:O2T.Germany,
Ophthotech Corp is a biopharmaceutical company. The Company is engaged in the development of novel therapeutics to treat diseases of the back of the eye, developing therapeutics for age-related macular degeneration.

Top Ranked Articles about Ophthotech Corp

Steven Cohen Adds to Fairmount Santrol, Ophthotech Guru increases his positions in energy company, biopharmaceutical company
Steven Cohen (Trades, Portfolio), founder and CEO of Point72 Asset Management, increased his position in two holdings recently. He increased his holding in Fairmount Santrol Holdings Inc. (NYSE:FMSA) by 21.2% on Dec. 7 and increased his position in Ophthotech Corp. (NASDAQ:OPHT) by 128.9% on Dec. 8. Read more...

Ratios

vs
industry
vs
history
P/S 3.13
OPHT's P/S is ranked higher than
78% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. OPHT: 3.13 )
Ranked among companies with meaningful P/S only.
OPHT' s P/S Range Over the Past 10 Years
Min: 3.11  Med: 35.25 Max: 70.15
Current: 3.13
3.11
70.15
EV-to-EBIT 1.00
OPHT's EV-to-EBIT is ranked higher than
90% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. OPHT: 1.00 )
Ranked among companies with meaningful EV-to-EBIT only.
OPHT' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.3  Med: -12.8 Max: 1.01
Current: 1
-37.3
1.01
EV-to-EBITDA 1.00
OPHT's EV-to-EBITDA is ranked higher than
91% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. OPHT: 1.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPHT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.7  Med: -12.9 Max: 1.01
Current: 1
-37.7
1.01
Current Ratio 6.07
OPHT's Current Ratio is ranked higher than
62% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OPHT: 6.07 )
Ranked among companies with meaningful Current Ratio only.
OPHT' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 16.13 Max: 40.94
Current: 6.07
0.34
40.94
Quick Ratio 6.07
OPHT's Quick Ratio is ranked higher than
63% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. OPHT: 6.07 )
Ranked among companies with meaningful Quick Ratio only.
OPHT' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 16.13 Max: 40.94
Current: 6.07
0.34
40.94
Days Sales Outstanding 175.88
OPHT's Days Sales Outstanding is ranked lower than
87% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. OPHT: 175.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPHT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.49  Med: 19.8 Max: 175.88
Current: 175.88
8.49
175.88

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.09
OPHT's Price/Median PS Value is ranked higher than
97% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. OPHT: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
OPHT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 0.97 Max: 1.64
Current: 0.09
0.09
1.64
Earnings Yield (Greenblatt) (%) 103.44
OPHT's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. OPHT: 103.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPHT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -20.01  Med: 0 Max: 1564.06
Current: 103.44
-20.01
1564.06

More Statistics

Revenue (TTM) (Mil) $50.37
EPS (TTM) $ -4.62
Beta1.86
Short Percentage of Float22.67%
52-Week Range $4.53 - 65.96
Shares Outstanding (Mil)35.70

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 259 170 519 963
EPS ($) 0.60 -3.10 -1.45 -1.05
EPS w/o NRI ($) 0.60 -3.10 -1.45 -1.05
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for OPHT

Headlines

Articles On GuruFocus.com
Steven Cohen Adds to Fairmount Santrol, Ophthotech Dec 16 2016 
Largest Insiders' Trades of the Week May 27 2016 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Weekly 3-Year Low Highlight: VIV, CNHI, WTW, OPHT Nov 17 2013 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Other Websites
Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against Ophthotech... Jan 19 2017
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces a Class Action Lawsuit Against Ophthotech... Jan 19 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 19 2017
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ophthotech... Jan 18 2017
Lifshitz & Miller Law Firm Announces Investigation of Abeona Therapeutics Inc., Agile Therapeutics,... Jan 18 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech... Jan 17 2017
OPHT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action... Jan 17 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 17 2017
OPHTHOTECH CORP. Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities Jan 17 2017
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who... Jan 12 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Jan 11 2017
SHAREHOLDER COMPLAINT: Levi & Korsinsky, LLP Files in U.S. District Court to Recover Losses Suffered... Jan 11 2017
OPHTHOTECH CORP. Files SEC form 8-K, Termination of a Material Definitive Agreement Jan 06 2017
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron... Dec 28 2016
Learn to Shift Gears in Your Trading Dec 17 2016
Steven Cohen Adds to Fairmount Santrol, Ophthotech Dec 16 2016
OPHTHOTECH CORP. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Other Events Dec 16 2016
Valeant, HiMax Lead Thursday’s 52-Week Low Club Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)